This site is intended for health professionals only

Embattled Astra sees profits fall

teaser

Pharmaceutical giant AstraZeneca has unveiled a fall in first-quarter profits as its best-selling drugs came under pressure from generic rivals.

The group said sales of ulcer treatment Nexium had fallen 9% to £623m, before adding that it expects a “single digit” sales decline in the product this year.

The group, which recently settled a patent dispute with an Indian firm over Nexium, also wrote off £130.1m over a potential generic threat to cancer treatment Ethyol.

Overall pre-tax profits slipped 15% to £1.08bn, lower than expected by the City.

Shares fell almost 5% on the back of the results.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE
Advertisement

Astra also booked a further £59.2m in costs from its restructuring plans announced last summer, under which it aims to axe 7,600 jobs worldwide.

Chief executive David Brennan pointed to a “growing pipeline” of new medicines – with three regulatory filings due this year – and insisted the firm is on track to meet its full-year targets.

But other Astra products under pressure from generic copies include angina drug Toprol-XL, where sales slumped 60% to £96.1m.

The group said the fall in revenues had been offset by the inclusion of sales from vaccines business MedImmune, which it bought last year.

Copyright © PA Business 2008

AstraZeneca






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

×